echosens

What echosens does

Echosens SA is a Paris-headquartered, privately held medical device company founded in 1999 that has pioneered non-invasive liver diagnostics for over 25 years. Its flagship product, FibroScan, is built on proprietary Vibration Controlled Transient Elastography (VCTE), which measures liver stiffness (fibrosis) and steatosis (fat) via Controlled Attenuation Parameter (CAP) in under 10 minutes at the point of care, eliminating the need for invasive liver biopsy in many clinical scenarios. The technology is supported by 6,000+ peer-reviewed publications and 250+ international clinical guidelines, and FibroScan is recognized as the global reference standard for non-invasive liver assessment across 127+ countries.

The product portfolio spans multiple FibroScan hardware variants (630 Expert, 530 Compact, PRO, Q, HANDY, BOX), the next-generation Guided VCTE technology, the cloud-based Liver Health Management (LHM) platform with clinical decision support, FibroScan-based diagnostic scores (FAST, Agile 3+, Agile 4), the myFibroScan patient portal, and the LHM Research clinical trial services platform for pharmaceutical MASH/NASH drug development. Revenue is generated through hardware device sales, software subscriptions and platform services, post-warranty service and maintenance contracts, and pharma clinical trial services.

Echosens serves hepatologists, gastroenterologists, hospitals, hepatology centers, primary care and endocrinology practices (for metabolic liver screening), and pharmaceutical companies running MASH/NASH clinical trials. Distribution is via a global certified distributor network supplemented by direct sales to major accounts, with dedicated regional service infrastructure in North America, EMEA, APAC, Latin America, and Africa. The company is led by CEO Romain Baujard and operates without any disclosed parent company, private equity backing, or public listing despite 25+ years of independent operation.

Name

echosens

Legal name

Echosens SA

Website

https://echosens.us

Company type

Private

Founded year

1999

Operating status

Operating

Short description

Echosens is a Paris-based private medical device company that develops and distributes FibroScan, the non-invasive gold-standard device for liver fibrosis and steatosis assessment using proprietary VCTE elastography, sold across 127+ countries to hepatologists, hospitals, and pharmaceutical clinical trial sponsors.

Ownership category

akta.pro rank

Product category

Medical Diagnostic Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ultrasound & Echography Systems (HLAHABAD)

akta.pro secondary industry

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Liver elastography devices
• Non-invasive diagnostics
• Medical imaging systems
• Liver fibrosis assessment
• Hepatic steatosis measurement

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. FibroScan Medical Device Sales: Sale of FibroScan hardware devices including FibroScan 630 Expert, FibroScan 530 Compact, FibroScan PRO, FibroScan Q, FibroScan HANDY, and FibroScan BOX. Revenue from initial device acquisition with associated software licenses. New products come with 12-month warranty plus 2 months for logistics and installation.
2. Software Subscriptions and Platform Services: Cloud-based Liver Health Management (LHM) platform subscription services, myFibroScan patient portal access, and FibroScan-based Scores biomarker services. Annual subscription model for platform access and data management.
3. Service and Maintenance Contracts: Post-warranty service contracts, probe calibration services (explicitly separate from warranty), and technical support services. Replacement parts provided under 12-month coverage.
4. Clinical Trial Services (LHM Research): Specialized services for pharmaceutical clinical trials including standardized examination data collection, quality control, and regulatory-grade reporting for drug development programs.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels8 records

Core offering

Echosens develops, manufactures, and sells FibroScan, a non-invasive medical device that uses proprietary Vibration-Controlled Transient Elastography (VCTE) technology to measure liver stiffness (fibrosis) and steatosis (fat) for the diagnosis and monitoring of chronic liver disease. The company complements its hardware devices with a software ecosystem including the Liver Health Management (LHM) cloud platform, FibroScan-based diagnostic Scores (FAST, Agile 3+, Agile 4), the myFibroScan patient portal, and the LHM Research clinical trial solution for pharmaceutical sponsors.

Product overview

Echosens offers FibroScan®, the gold standard non-invasive solution for liver disease assessment, delivered through a portfolio of hardware devices and software platforms. The core product line includes FibroScan® devices in multiple variants (630 Expert, 530 Compact, PRO, Q, HANDY, BOX) that use proprietary VCTE® (Vibration-Controlled Transient Elastography) technology to measure liver stiffness and controlled attenuation parameter (CAP) for fat assessment. The ecosystem includes Liver Health Management (LHM) cloud platform for clinical decision support, FibroScan®-based Scores (Fast™, Agile 3+, Agile 4) for enhanced diagnostic biomarkers, myFibroScan patient portal, LHM Research for pharma clinical trials, and Guided VCTE® as the next-generation examination technology. This integrated portfolio supports the entire liver disease diagnostic pathway from screening to monitoring across 127+ countries.

Differentiator

Problem solved

Functional benefit

Brands

• FibroScan: The company's flagship non-invasive liver elastography device for assessing liver fibrosis and steatosis
• VCTE (Vibration Controlled Transient Elastography)
• Liver Health Management (LHM)
• myFibroScan
• LHM Research
• FibroMeter
• FAST Score
• Agile 3+
• Agile 4
• Guided VCTE
• Echosens Academy

Products and services

• FibroScan 630 Expert

Quantifiable outcome

• 6,000+ peer-reviewed publications support FibroScan/VCTE clinical performance
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature8 records

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Genfit: Biotech with a diagnostic biomarker franchise (NIS4) for NASH/MASH identification, representing a blood-based alternative to FibroScan for patient screening and stratification.
• Samsung Medison: Subsidiary of Samsung offering premium ultrasound with elastography (e.g., RS85 with S-Shearwave), competing with FibroScan at the high end of hospital imaging suites.
• Mindray: Lower-cost ultrasound vendor adding elastography capabilities to its platform, increasing price competition for non-invasive liver assessment, particularly in cost-sensitive markets.
• Perspectum: Developer of LiverMultiScan, an MRI-based multiparametric liver assessment, providing an alternative non-invasive diagnostic for MASLD/MASH and competing for the same clinical decision budgets.
• Resonance Health: Provides MRI-PDFF-based liver fat quantification, already cited by Echosens itself as a reference standard for CAP, representing a credible non-invasive alternative in research and pharma settings.

Direct peers

• Siemens Healthineers: Major imaging incumbent whose ACUSON ultrasound family includes shear wave elastography for liver fibrosis assessment, directly competing with FibroScan in hospital radiology and hepatology departments.
• GE HealthCare: Ultrasound leader offering 2D shear wave elastography on LOGIQ platforms, providing clinicians a 'good enough' liver stiffness measurement bundled into broader ultrasound fleet purchases.
• Canon Medical Systems: Aplio i-series ultrasound systems offer shear wave elastography for liver fibrosis, providing another hospital-grade alternative to VCTE-based FibroScan exams.
• Philips: Operates in liver imaging through its EPIQ and Affiniti ultrasound systems with ElastPQ quantification, competing for the same hospital budgets as FibroScan for liver assessment.

Others

• Clario: Clinical trial technology and imaging CRO with deep NASH/MASH trial infrastructure. Competes for pharma-services spend alongside Echosens' LHM Research, particularly for imaging endpoint management in liver trials.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/echosens
• YouTubevimeo.com/echosens
• Facebookfacebook.com/fibroscan.echosens
• LinkedInlinkedin.com/company/echosens

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about echosens